Enzolytics (ENZC) Stock Attempts To Recovery: Will The Rally Continue?

In the past two weeks, the Enzolytics Inc (OTCMKTS:ENZC) stock has been on the radars of many investors and that becomes far more apparent from the price action in the stock. The stock has recorded gains of 35% during that period and the rally continued on Tuesday.

Yesterday, it jumped by as much as 15.5% and in this sort of situation; it might be a good idea for investors to take a closer look at the company. One of the more important positive triggers for the stock came about on May 26 when the company announced that it had managed to identify immutable sites on the HTLV-1 virus.

It is a major development since it is going to help Enzolytics in its work to product monoclonal antibodies that are supposed to work against the HTLV-1 virus. In this regard, investors need to keep in mind that at this point there are no effective vaccines in the market that can actually tackle the HTVL-1 virus.

While this discovery was an important factor behind the rally in the Enzolytics stock, it is important to mention that there were some other important developments as well. In the middle of May, it was announced that Enzolytics collaborated with Intel Corporation to publish a white paper.

The white paper, titled “Optimizing Empathetic A.I. to Cure Deadly Diseases”, pointed out that the innovative approach of Enzolytics and the artificial intelligence analytics tools of Intel could be combined to produce effective treatments meant for all types of virus infections. This white argues that in the future the aim of healthcare is going to be more anticipatory than reactionary.

Back in April the company had also made an announcement with regards to the sort of progress it has made on a range of initiatives including the one related to its multiple therapeutics platform. It is now going to be interesting to see if the Enzolytics stock can maintain its momentum in the coming days.

Atossa Therapeutics (ATOS) Stock Is About To Hit New Highs: How to Trade?

Over the course of the past six weeks, the Atossa Therapeutics (NASDAQ:ATOS) stock has been in the middle of a strong rally and during that period, it managed to deliver gains of as much as 160%.

The Atossa stock kicked off the month of June on a strong note as well and clocked gains of as much as 20% yesterday. There was no announcement from the company yesterday but an analyst actually raised his price target for the Atossa stock and that seems to have come as a major trigger for the rally in the stock. Hence, it might be a good idea now for investors to take a closer look at the stock.

In a new development, analyst Edward Woo raised the target price for the Atossa stock from $7.75 a share to $8 a share. However, it should be noted that the new target price is just more than double the previous closing price of the stock. On the other hand, Woo maintained the buy rating on the stock.

One of the biggest reasons behind the bullish sentiments about the Atossa stocks is its oral breast cancer product named Endoxifen. Breast cancer is a widespread disease and it is believed that Endoxifen could eventually add substantially to the company’s revenues.

Back in February, Atossa also conducted a phase 2 clinical study of the product in Australia and announced that the results were ‘overwhelmingly positive’. The comment was in relation to the effectiveness of the product in reducing the activity of tumour cells.

In addition to that, the company has also managed to come up with two medications that are meant to treat patients suffering from COVID 19. In this regard it is also important to note that Woo has been bullish about the stock for quite some time and had given a buy rating to Atossa in September last year.

Skip to content